» Articles » PMID: 9582300

Energy Thresholds in Brain Mitochondria. Potential Involvement in Neurodegeneration

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 1998 May 28
PMID 9582300
Citations 124
Authors
Affiliations
Soon will be listed here.
Abstract

Decreases in mitochondrial respiratory chain complex activities have been implicated in neurodegenerative disorders such as Parkinson's disease, Huntington's disease, and Alzheimer's disease. However, the extent to which these decreases cause a disturbance in oxidative phosphorylation and energy homeostasis in the brain is not known. We therefore examined the relative contribution of individual mitochondrial respiratory chain complexes to the control of NAD-linked substrate oxidative phosphorylation in synaptic mitochondria. Titration of complex I, III, and IV activities with specific inhibitors generated threshold curves that showed the extent to which a complex activity could be inhibited before causing impairment of mitochondrial energy metabolism. Complex I, III, and IV activities were decreased by approximately 25, 80, and 70%, respectively, before major changes in rates of oxygen consumption and ATP synthesis were observed. These results suggest that, in mitochondria of synaptic origin, complex I activity has a major control of oxidative phosphorylation, such that when a threshold of 25% inhibition is exceeded, energy metabolism is severely impaired, resulting in a reduced synthesis of ATP. Additionally, depletion of glutathione, which has been reported to be a primary event in idiopathic Parkinson's disease, eliminated the complex I threshold in PC12 cells, suggesting that antioxidant status is important in maintaining energy thresholds in mitochondria. The implications of these findings are discussed with respect to neurodegenerative disorders and energy metabolism in the synapse.

Citing Articles

Neurodegenerative disorders, metabolic icebergs, and mitohormesis.

Phillips M, Picard M Transl Neurodegener. 2024; 13(1):46.

PMID: 39242576 PMC: 11378521. DOI: 10.1186/s40035-024-00435-8.


The Effect of Neuronal CoQ Deficiency and Mitochondrial Dysfunction on a Rotenone-Induced Neuronal Cell Model of Parkinson's Disease.

Millichap L, Turton N, Damiani E, Marcheggiani F, Orlando P, Silvestri S Int J Mol Sci. 2024; 25(12).

PMID: 38928331 PMC: 11204355. DOI: 10.3390/ijms25126622.


Assessing the mitochondrial safety profile of the molnupiravir active metabolite, β-d-N4-hydroxycytidine (NHC), in the physiologically relevant HepaRG model.

Kiy R, Khoo S, Chadwick A Toxicol Res (Camb). 2024; 13(1):tfae012.

PMID: 38328743 PMC: 10848230. DOI: 10.1093/toxres/tfae012.


Mitochondrial Proteomes in Neural Cells: A Systematic Review.

Nusir A, Sinclair P, Kabbani N Biomolecules. 2023; 13(11).

PMID: 38002320 PMC: 10669788. DOI: 10.3390/biom13111638.


Creatine as a Therapeutic Target in Alzheimer's Disease.

Smith A, Morris J, Carbuhn A, Herda T, Keller J, Sullivan D Curr Dev Nutr. 2023; 7(11):102011.

PMID: 37881206 PMC: 10594571. DOI: 10.1016/j.cdnut.2023.102011.